NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Imm... NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It also provides NEXI-004 which is in preclinical stage for EBV related diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.0001 | 0.0001 | 0.0001 | 186 | 0.0001 | CS |
| 4 | 0 | 0 | 0.0001 | 0.0001 | 0.0001 | 853 | 0.0001 | CS |
| 12 | 0 | 0 | 0.0001 | 0.0001 | 0.0001 | 810 | 0.0001 | CS |
| 26 | 9.9E-5 | 9900 | 1.0E-6 | 2.17 | 1.0E-6 | 1975 | 0.45515102 | CS |
| 52 | 0 | 0 | 0.0001 | 2.17 | 1.0E-6 | 1401 | 0.29254709 | CS |
| 156 | -2.4999 | -99.996 | 2.5 | 3.23 | 1.0E-6 | 10066 | 1.73271941 | CS |
| 260 | -2.4999 | -99.996 | 2.5 | 3.23 | 1.0E-6 | 10066 | 1.73271941 | CS |
glenngroove
4分前
Guido2
5分前
mikeo56
6分前
meirluc
7分前
Ammarmalhas
8分前
AJH92
8分前
north40000
9分前
Denn55
11分前
Denn55
11分前
BBANBOB
15分前
kevone401
18分前
jjjjjjjj
18分前
srinsocal
21分前
Truthsocial
21分前
poguemahone
23分前
SSKILLZ1
28分前
LocWolf
29分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。